解析多发性硬化症中的肠道微生物组成。
Breaking down the gut microbiome composition in multiple sclerosis.
机构信息
Department of Clinical Neurological Sciences, Division of Neurology, University Hospital, London, ON, Canada.
Division of Infectious Diseases, St. Joseph's Health Care, London, ON, Canada.
出版信息
Mult Scler. 2017 Apr;23(5):628-636. doi: 10.1177/1352458516682105. Epub 2016 Dec 12.
BACKGROUND
The gut microbiome, which consists of a highly diverse ecologic community of micro-organisms, has increasingly been studied regarding its role in multiple sclerosis (MS) immunopathogenesis. This review critically examines the literature investigating the gut microbiome in MS.
METHODS
A comprehensive search was performed of PubMed databases and ECTRIMS meeting abstracts for literature relating to the gut microbiome in MS. Controlled studies examining the gut microbiome in patients with MS were included for review.
RESULTS
Identified studies were predominantly case-control in their design and consistently found differences in the gut microbiome of MS patients compared to controls. We examine plausible mechanistic links between these differences and MS immunopathogenesis, and discuss the therapeutic implications of these findings.
CONCLUSIONS
Review of the available literature reveals potential immunopathogenic links between the gut microbiome and MS, identifies avenues for therapeutic advancement, and emphasizes the need for further systematic study in this emerging field.
背景
肠道微生物组由高度多样化的微生物生态群落组成，其在多发性硬化症（MS）发病机制中的作用越来越受到关注。本综述批判性地评估了关于 MS 肠道微生物组的文献。
方法
对 PubMed 数据库和 ECTRIMS 会议摘要进行了全面检索，以查找与 MS 肠道微生物组相关的文献。纳入了研究 MS 患者肠道微生物组的对照研究进行综述。
结果
确定的研究主要为病例对照设计，一致发现 MS 患者的肠道微生物组与对照组存在差异。我们检查了这些差异与 MS 发病机制之间可能存在的机制联系，并讨论了这些发现的治疗意义。
结论
对现有文献的综述揭示了肠道微生物组与 MS 之间潜在的发病机制联系，确定了治疗进展的途径，并强调了在这个新兴领域进一步系统研究的必要性。
Zotero 插件